Foundation Medicine — Investor Presentation (January 2014)
28 slides from Foundation Medicine's investor presentation, Jan 13, 2014

Slide 1: The Molecular Information Company
Exhibit 99.2 Exhibit Foundation The Molecular 99.2Medicine Information Company

Slide 2: Forward-Looking Statements
Forward These Such the updated and All FoundationOne inability Foundation Medicine’s Any except 2©2013 market forward-looking the forward-looking forward slides as Foundation delivery version of Looking required size Foundation subsequent Medicine’s and looking for Heme of the Statements by Foundati

Slide 3: Our Vision
OurFoundation At 3©2013 Vision Foundation Medicine, Medicine, we are Inc.leading a transformation in cancer care, where each patient’s treatment is informed by a deep understanding of the molecular changes that contribute to their disease.

Slide 4: 2013: A Year of Rapid Progress
2013: A$121 >9,000 Approximately Published Launched Raised Expanded Named 4©2013 Foundation clinical aYear “Best FoundationOne 16 keymillion to apeer-reviewed Of BioPharma new tests Place $29 Rapid Medicine, facility million delivered intoSeptember Progress Work” Heme relationships and revenue manus

Slide 5: Translating Cancer Genomes into Actionable Information
Translating Cancer Gene Delivering 5©2013 Alterations Foundation Cells Genesand Each integrating Cancer’s Medicine, actionable Genome Inc. comprehensive molecular information into routine treatment of cancer

Slide 6: FMI BioPharma: Every Cancer Cell Tells a Story
FMI BioPharma Molecular Every Sticky User >18 BioPharma >90 Value Ordered Clinical 6Future alliances Value interface delivered Dataset experience opportunities byInformation Thesis: thousands signed Adds tothrough clinical translate for Three to inphysicians/pharma of Value Platform cancer trials te

Slide 7: Case Presentation
7Case Presentation

Slide 8: Case Presentation: Non-Small Cell Lung Cancer / CUP
CASE2012, “Non-Small May 8©2013 PRESENTATION Foundation 58 Cell y.o.Lung female Medicine, Cancer”/Cancer presented Inc. withOfnew Unknown onset ofPrimary seizures(CUP) and was diagnosed with stage IV lung adenocarcinoma with brain metastasis

Slide 9: Case Presentation: Initial Course
CASE2012, May Initial Brain September PET/CT 9©2013 mass Course PRESENTATION Foundation revealed 2012 58 completely y.o.no metabolically female Medicine, change resected presented inInc. abdominal active with 2 xnew 4mass cmonset left and mid seizures slightly abdominal increased and wasmass diagnos

Slide 10: Case Presentation: Negative Initial Testing, FoundationOne Findings
CASE Initial Negative FoundationOne™ Identified Based January Scan May Revealed November 12 ©2013 10 months 2013, revealed molecular on PRESENTATION Foundation 2013, for the no MET durable 2012, 2013, PET/CT evidence EGFR findings aPET/CT amplification 40% testing crizotinib PET/CT testing response

Slide 11: FoundationOne Report: Crizotinib, MET inhibitor
FoundationOne Crizonib, 11 METi Report ©2013 Foundation Medicine, Inc.

Slide 12: FoundationOne Results and Takeaways
FoundationOne Takeaways Results Crizotinib Suggests Patient ©2013 12 Foundation with recently led benefit commenced tometastatic therapy identified visited of Medicine, FoundationOne with disease symptomatic FMIalteration FDA-approved and Inc. (CUP) is leaving in that and now cost isradiographic not

Slide 13: A 100K Annual Initial Target Market Opportunity
A 100K Annual ~ Initial Potentially Additional US ~2M ~100K ~1M ©2013 13Major Annual Solid use Foundation Heme Target new New inopportunities + expanding Prevalence patients refractory Heme Market Market Medicine, annually Opportunity to for =cases ~2 related ~5M FoundationOne™ million except Inc. p

Slide 14: Rapid Adoption of FoundationOne
Tests 4,000 (unaudited) 1,000 1,140 1,500 1,626 2,000 2,500 2,577 3,000 3,500 500 492 0Q Rapid ©2013 142-12 244 Reported 3,750 878 Adoption adoption Q3-12 Foundation Q4-12 to bolstered Ofordering Medicine, FoundationOne Q1-13byphysicians Q2-13 growing Inc. Q3-13 salesQ4-13 team and repeat orders

Slide 15: Targeted Tests Are Inadequate for Individual Diagnostic Needs
TargetedFoundation Individual ©2013 15 Diagnostic and panelMedicine, Model tests focused Is Inc. Inadequate on one or a group of genes do not reflect the full spectrum and evolving understanding of cancer

Slide 16: Legacy Diagnostic Tools Miss Genes and Alterations
Legacyalterations Non-Small Genes Alterations Many Gene Percentage of cases with ©2013 with Foundation Diagnostic Cell Traditional Actionable Alterations, Lung can Tools Medicine, be Cancer Alterations Gene Actionability addressed MissMarkers Example Inc. Therapeutic 16 with Unknown Commonly (2012)

Slide 17: You Cannot Treat What You Do Not Understand
foundationOne 05Number Focal STK11 RB1 CDKN2B CDKN2A KRAS EGFR TP53 200 150 100 You MYC MDM2 MCL1 cannot PTPRD CDK4 LRP1B NF1 RICTOR ERBB2 ©2013 ALK NKX2_1 SOX2 PTEN Non-Small 57% DNMT3A CCNE1 SMAD4 Foundation APC you ATM do FGFR1 AKT2 4% Inc. BRAF Medicine, Base CCND3 NOTCH1 TET2 MET Insertions/del

Slide 18: Current Esoteric Testing Model Is Unsustainable
Current Esoteric Specific Reference Special Initial Hospital Time Especially ©2013 Time diagnostic Foundation stains, Model Lab molecular Lab Unsustainable TimeFISH, Broken work-up tests: Medicine, HER2, For KRAS, forPhysicians ER, Payors Inc.BRAF, PR, 18Total EGFR, &EGFR, Payers Costs etc…etc…

Slide 19: The Breakthrough Solution: FoundationOne
Themajor Breakthrough Less Ordered Laboratory All Base Insertions Copy 236 Rearrangements Includes +169 +265 >99% ©2013 19 Genes FMI Time, substitutions genes number sensitivity Foundation by additional Solution: classes and Cost developed Oncologist foralterations Breadth deletions DNA RNA and and

Slide 20: Interactive Cancer Explorer (ICE)
ICE:decisions consultation Delivers references Enables Developing enable outcomes Provides inform Creates Building team Interactive care ©2013 20 Creating based sharing physician Foundation aphysicians FoundationOne additional dedicated community data and Cancer in expanding with Bay And while clini

Slide 21: Diversity of Alterations Confers Actionability
Diversity, 82% linked FDA Open confers A information by FoundationOne patients treatment Dataset: ©2013 21 maximum other of approved clinical to: Foundation FoundationOne greater who 3,936 available status Actionability would of lack trial qualifying targeted likelihood 31% Experience provides quogo

Slide 22: Pharma Insights and Collaborations
PharmaFoundation Insights Resurrected Enhanced Created Enabled Evolving Continues ©2013 22 Solutions combo delivered new to clinical tobroad lagging inform target Tx–trial have strategic opportunities Medicine, discovery/ Partner or enhancements design failed collaborations Ofassets Inc. validation

Slide 23: Case Presentation: AstraZeneca
CASE December AstraZeneca FMI September AZ ©2013 23 announced Analysis partnered PRESENTATION Foundation 2011 2013 identifies announced with the initiation Medicine, AZato that new conduct of its path Inc. two oral for retrospective Phase PARP olaparib 3inhibitor, studies analysis inolaparib, ovaria

Slide 24: Reimbursement Strategy and Payor Engagement
Reimbursement Analytic Setting leading for and cancer Payor Early payor development published peer-reviewed Comprehensive ©2013 24 test performance and relationship Engagement centers Foundation validation industry- benchmark Validation expansive in economic conferences journals and Strategy Driving

Slide 25: Key Studies Driving Adoption
Adoption Key Studies HER2 Completed Fusion ALK “Decision In-process Pan NSCLC FoundationOne Phase Pediatric Rare Randomized Planned Earlier Initial ©2013Negative drivers Tumors FISH 1data FISH Stage Concordance Foundation Analytic Matched (BATTLE Relapsed & Impact” from –Reimbursement –Trial, Diseas

Slide 26: Financial Summary: Quarter Ended September 30, 2013
Financial Quarter 2013 Revenue Cost Sales General Research Total Ended ©2013 of 2012 costs and Q3 Foundation revenues Ended and $8,208 and Summary marketing with 2013 and administrative development September expenses $138M $2012 2,858 3,037 Medicine, 3,038 in 1,791 $19,328 $19,322 cash 30, 849 6,988

Slide 27: 2014 Milestones and Guidance
2014 Milestones 22,000 $52–58 Product Expansion Additional ©2013 27 –Foundation million enhancements: 25,000 of Interactive FoundationOne total clinical AndMedicine, revenue Guidance Cancer reports –Inc. Explorer 1H delivered 2014features and outcomes capabilities – 2H 2014

Slide 28: Foundation Medicine: The Molecular Information Company
Foundation The Molecular Medicine Information Company
Source: SEC EDGAR · 8-K filed Jan 13, 2014
More decks from Foundation Medicine Inc
JP Morgan Healthcare Conference 201820 slides · Jan 8, 2018
J.P. Morgan Healthcare Conference (January 2017)17 slides · Jan 9, 2017
2016 J.P. Morgan Annual Healthcare Conference22 slides · Jan 11, 2016
Merger or Acquisition (January 2015)49 slides · Jan 14, 2015
Merger or Acquisition (January 2015)20 slides · Jan 12, 2015